Skip to main content

Advertisement

SpringerLink
Log in

Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Disease status is often measured with bounded outcome scores (BOS) which takes a discrete set of values on a finite range. The distribution of such data is often skewed, rendering the standard analysis methods assuming normal distribution inappropriate. Among the methods used for BOS analyses, two of them have the ability to predict the data within its natural range and accommodate data skewness: (1) a recently proposed beta-distribution based approach and (2) a mixture model known as CUB (combined uniform and binomial). This manuscript compares the two approaches, using an established mechanism-based longitudinal exposure-response model to analyze data from a phase 2 clinical trial in psoriatic patients. The beta-distribution–based approach was confirmed to perform well, and CUB also showed potential. A separate issue of modeling clinical trial data is that the collected baseline disease score range may be more limited than that of post-treatment disease score due to clinical trial inclusion criteria, a fact that is typically ignored in longitudinal modeling. The effect of baseline disease status restriction should in principle be adjusted for in longitudinal modeling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Overgaard RV, Ingwersen SH, Tornoe CW. Establishing good practices for exposure-response analysis of clinical endpoints in drug development. CPT Pharmacometrics Syst Pharmacol. 2015;4(10):565–75.

    Article  CAS  Google Scholar 

  2. Hu C, Zhou H, Sharma A. Landmark and longitudinal exposure-response analyses in drug development. J Pharmacokinet Pharmacodyn. 2017;44(5):503–7.

    Article  CAS  Google Scholar 

  3. Lesaffre E, Rizopoulos D, Tsonaka R. The logistic transform for bounded outcome scores. Biostatistics. 2007;8(1):72–85.

    Article  Google Scholar 

  4. Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2010;50(3):257–67.

    Article  CAS  Google Scholar 

  5. Hu C, Randazzo B, Sharma A, Zhou H. Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients. J Pharmacokinet Pharmacodyn. 2017;44(5):437–48.

    Article  CAS  Google Scholar 

  6. Iannario MP, D. A comprehensive framework of regression models for ordinal data. METRON. 2016;74(2):233–52.

    Article  Google Scholar 

  7. Hu C. On the comparison of methods in analyzing bounded outcome score data. AAPS J. 2019;21(6):102.

    Article  Google Scholar 

  8. Ursino M, Gasparini M. A new parsimonious model for ordinal longitudinal data with application to subjective evaluations of a gastrointestinal disease. Stat Methods Med Res. 2018;27(5):1376–93.

    Article  Google Scholar 

  9. Hu C, Zhou H, Sharma A. Applying Beta distribution in analyzing bounded outcome score data. AAPS J. 2020;22(3):61.

    Article  Google Scholar 

  10. Piccolo D, Simone R, Iannario M. Cumulative and CUB models for rating data: a comparative analysis. Int Stat Rev. 2019;87(2):207–36.

  11. Sharma A, Jusko WJ. Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1996;24(6):611–35.

    Article  CAS  Google Scholar 

  12. Hu C, Szapary PO, Mendelsohn AM, Zhou H. Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint. J Pharmacokinet Pharmacodyn. 2014;41(4):335–49.

    Article  Google Scholar 

  13. Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn. 2008;35:139–57.

    Article  CAS  Google Scholar 

  14. Hu C. Exposure-response modeling of clinical end points using latent variable indirect response models. CPT Pharmacometrics Syst Pharmacol. 2014;3:e117.

    Article  CAS  Google Scholar 

  15. Hu C, Zhou H. Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis. J Pharmacokinet Pharmacodyn. 2016;43(1):45–54.

    Article  Google Scholar 

  16. Hu C, Adedokun OJ, Chen Y, Szapary PO, Gasink C, Sharma A, et al. Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease. J Pharmacokinet Pharmacodyn. 2017;44(5):425–36.

    Article  CAS  Google Scholar 

  17. Hu C, Adedokun OJ, Zhang L, Sharma A, Zhou H. Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis. J Pharmacokinet Pharmacodyn. 2018;45(6):803–16.

    Article  CAS  Google Scholar 

  18. Hu C, Xu Y, Zhuang Y, Hsu B, Sharma A, Xu Z, et al. Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab. J Pharmacokinet Pharmacodyn. 2018;45(5):679–91.

    Article  CAS  Google Scholar 

  19. Hu C, Yao Z, Chen Y, Randazzo B, Zhang L, Xu Z, et al. A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis. J Pharmacokinet Pharmacodyn. 2018;45(4):523–35.

    Article  CAS  Google Scholar 

  20. Hu C, Zhou H, Sharma A. Facilitating longitudinal exposure-response modeling of a composite endpoint using the joint modeling of sparsely and frequently collected subcomponents. AAPS J. to appear.

  21. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–92.

    Article  CAS  Google Scholar 

  22. Hu C, Zhou H. An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol. 2008;48(7):812–22.

    Article  Google Scholar 

  23. Hu C, Zhang J, Zhou H. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat. 2011;10(1):14–26.

    Article  Google Scholar 

  24. Zhu Y, Hu C, Lu M, Liao S, Marini J, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting il-12/23p40, in patients with moderate to severe plaque psoriasis, J Clin Pharmacol. 2009;49(2):162–75.

  25. Hutmacher MM, French JL, Krishnaswami S, Menon S. Estimating transformations for repeated measures modeling of continuous bounded outcome data. Stat Med. 2011;30(9):935–49.

    Article  Google Scholar 

  26. Hu C, Xu Z, Mendelsohn A, Zhou H. Latent variable indirect response modeling of categorical endpoints representing change from baseline. J Pharmacokinet Pharmacodyn. 2013;40(1):81–91.

    Article  Google Scholar 

  27. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30(6):387–404.

    Article  Google Scholar 

  28. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user's guides (1989–2009). Ellicott City: Icon Development Solutions; 2009.

    Google Scholar 

  29. Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol. 2019;8(8):538–56.

  30. Karlsson MO, Holford NHG. A tutorial on visual predictive checks 2008 [updated 2008. Available from: www.page-meeting.org/?abstract=1434.

Download references

Funding

This research was funded by Janssen Research and Development, LLC.

Author information

Authors and Affiliations

  1. Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania, 19477, USA

    Chuanpu Hu, Honghui Zhou & Amarnath Sharma

Authors
  1. Chuanpu Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Honghui Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amarnath Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chuanpu Hu.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, C., Zhou, H. & Sharma, A. Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data. AAPS J 22, 95 (2020). https://doi.org/10.1208/s12248-020-00478-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-020-00478-5

KEY WORDS

Search

Navigation